Pelvic Floor DisordersNCT04826939
Intravaginal Devices for Pelvic Floor Motion
A study testing PFDx device and leva device in people with Pelvic Floor Disorders, run by University of Oklahoma at 2 sites in United States.
Trial summary
The leva and PFDx devices accurately reflect pelvic floor motion consistent with TPUS evaluation. During a voluntary PFM contraction, the change in angle from a position of rest to maximal effort that is detected by each device is positively correlated with TPUS measurements and Modified Oxford scores. Read more about this study
- Who is it for?
- Ages 18 to 100 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Pelvic Floor Disorders
- What is being tested?
- PFDx device and leva device
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 2 sitesUnited States
- Study dates
- 25 Mar 2021to 26 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Female
- 18 years of age or older
- Presence of a vagina
- Ability to read and write English
- BMI <30
- Reports they are able to perform a kegel exercise
Who cannot join
- Inability to perform a kegel exercise
- Pelvic organ prolapse greater than ICS POP-Q Stage II
- Known, untreated pelvic, vaginal or urinary tract infection
- Currently pregnant
Trial locations and contacts
2 sites in 1 country.
United States2 sites
OU Physicians
Oklahoma City, Oklahoma, 73104
University ofOklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
About this study
Official title: Validity (and Reliability) of Two Forms of an Accelerometer-Based Intravaginal Device for Detecting Pelvic Floor Motion
The leva and PFDx devices accurately reflect pelvic floor motion consistent with TPUS evaluation. During a voluntary PFM contraction, the change in angle from a position of rest to maximal effort that is detected by each device is positively correlated with TPUS measurements and Modified Oxford scores.
Read the detailed description
Thirty women 18 years or older will be recruited from OB/GYN, FPMRS or other clinics. Following informed consent and successful screening, subjects will undergo testing as outlined below. Five subjects (all will be invited until five subjects have agreed) will return to clinic in 1-2 weeks to undergo repeat testing using all modalities.
After obtaining informed consent, subject information will be collected, including demographic data, BMI, and medical history (including ob/gyn history). Subjects will complete urinalysis for pregnancy. Subjects will also complete the Pelvic Floor Distress Inventory (PFDI-20) questionnaire. All subjects will undergo a complete pelvic examination including pelvic organ prolapse quantification (POP-Q), a digital assessment of PFM strength (Modified Oxford Scale) and receive a TPUS. Subjects will also complete a series of PFM contractions using the leva and PFDx devices to measure angle changes, and undergo vaginal assessment with a perineomter.
Pelvic floor muscle assessment Prior to recording device measurements, a correct pelvic floor muscle contraction will be verified via manual pelvic floor assessment. Subjects will be instructed to perform a "lift-and-squeeze" maneuver of the pelvic floor, and correct PFM contraction will be verified by the primary examiner (LHQ). PFM strength will then be assessed via digital palpation by the examiner inserting the first and/or second fingers approximately 4 cm into the vagina and palpating the right and left PFM during contraction. Strength will be graded according to the 6-point Modified Oxford Scale (0=no contraction; 1='flicker'; 2=weak; 3=moderate; 4=good; 5=strong). The mean score of the right and left sides of the vagina will be calculated and used for correlation analysis.
Perineometry PFM strength will be measured using a Peritron™ perineometer, which is a 28mm diameter compressible probe connected to a handheld microprocessor. It provides readings of pelvic floor contraction in cm of H20 with precision up to one decimal point, and it has been demonstrated to show reproducible and reliable measurements. The resting vaginal pressure and two peak pressures will be measured. For this study, PFM strength is defined as the augmented vaginal pressure, calculated by measuring the average of 2 peak pressures minus the resting vaginal pressure.
TPUS measurements TPUS imaging will be completed at the time of the study visit using the BK Medical Ultrafocus (Peabody, MA) and 8802 transperineal transducer. The probe will be covered with ultrasound gel and a probe cover. All ultrasound studies will be performed in the office setting with the patient in the dorsal lithotomy position, with hips flexed and abducted. No preparation is required, and no rectal or vaginal contrast will be used. Patients will be instructed to arrive at the office with a partially full bladder and to avoid excessive pressure on surrounding structures that might distort the anatomy. In the sagittal view, dynamic ultrasound parameters will be measured relative to a horizontal reference line at the level of the infero-posterior margin of the pubic symphysis. Dynamic images will be obtained during PFM contractions and at rest. At least 3 cycles of PFM contraction and relaxation will be recorded for each individual.
Baseline assessment will be performed at rest, then with 3 maximum-effort voluntary contraction (MVC). Ultrasound measurements will include: Anterior-posterior distance (APD) of the levator hiatus to the pubic bone (primary aim), levator urethra gap (LUG), distance from bladder neck to the pubic bone and distance of the midurethra to the pubic bone. Urethral angle at rest and with max contraction will also be measured. The cravioventral shift of the levator plate relative to a vertical line of reference relative to the anorectal angle will also be measured.
Leva measurements Subjects will be instructed on proper insertion and placement of the leva device. The examiner will assist with device placement, as needed. With the leva inserted, subjects will assume a standing position. Subjects will complete a series of pelvic floor muscle training (five lifts for 15 seconds of maximum lift, followe by 15 seconds of rest).
PFDx measurements The examiner will place the PFDx in the vagina, ensuring the ring component is positioned at the fornix with the extension running the length of vagina and out of the body. With the device retained in the vagina, subjects will assume a standing position. Angle measurements will be recorded at rest and with maximal voluntary 'lift-and-squeeze' contraction. These measurements will be repeated at least 3 times with 1-minute rest between each measurement.
- Conditions
- Pelvic Floor Disorders
- Being tested
- PFDx device and leva device
- Medical subject headings
- Pelvic Floor Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PFDx device and leva deviceDevice
Participants will use the leva device, PFDx device and undergo ultrasound measurements during pelvic floor motion to compare the three measurements.
| Study group | Role | What they receive |
|---|---|---|
| Device usage | Experimental | All participants will complete a survey and undergo an evaluation to test the movement of their pelvic floor with the PFDx device and leva device Receives: Device: PFDx device and leva device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Validate leva measurements with transperineal ultrasound (TPUS)
During a voluntary pelvic floor muscle contraction, the change in angle from a position of rest to maximal effort that is detected by the leva device will be compared to the change in distance from the pubic bone to the levator plate measured by 2D TPUS during the same task.
Measured: Through final study visit (about 3 months)
Secondary outcomes (9)
Compare leva angle change measurements with Modified Oxford, Brinks
Modified Oxford, Brinks is a commonly used clinical assessment tool to measure pelvic floor muscle strength
Measured: Through final study visit (about 3 months)
Compare PFDx angle change measurements with Modified Oxford, Brinks
Modified Oxford, Brinks is a commonly used clinical assessment tool to measure pelvic floor muscle strength
Measured: Through final study visit (about 3 months)
Compare PFDx to a perineometer
Measuring angle change measurements with change in vaginal squeeze pressure
Measured: Through final study visit (about 3 months)
Compare leva to a perineometer
Measuring angle change measurements with change in vaginal squeeze pressure
Measured: Through final study visit (about 3 months)
Determine the test-retest reliability of Manual muscle testing angle measurements over 2 time points
Time points are 1-2 weeks apart
Measured: Through final study visit (about 3 months)
Determine the test-retest reliability of perineometry angle measurements over 2 time points
Time points are 1-2 weeks apart
Measured: Through final study visit (about 3 months)
Determine the test-retest reliability of ultrasound angle measurements over 2 time points
Time points are 1-2 weeks apart
Measured: Through final study visit (about 3 months)
Determine the test-retest reliability of leva angle measurements over 2 time points
Time points are 1-2 weeks apart
Measured: Through final study visit (about 3 months)
Determine the test-retest reliability of PFDx angle measurements over 2 time points
Time points are 1-2 weeks apart
Measured: Through final study visit (about 3 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2021
- Study start25 Mar 2021
- Primary completion26 Sep 2022
- Study completion26 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pelvic Floor DisordersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oklahoma
- Sponsor type
- University, hospital or other
- Collaborators
- Renovia, Inc.
- Responsible party
- Sponsor
- Investigators
- Lieschen Quiroz, MD, Principal investigator, University of Oklahoma HSC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04826939
- Sponsor's protocol ID
- 13114
- Status last verified
- Jun 2023
- First submitted
- 4 Mar 2021
- Last updated
- 13 Jun 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: No plans to share information
Study at a glance
From the registry record, last updated by the sponsor on 13 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validity (and Reliability) of Two Forms of an Accelerometer-Based Intravaginal Device for Detecting Pelvic Floor Motion
- ClinicalTrials.gov ID
- NCT04826939
- Acronym / sponsor ID
- 13114
- Conditions
- Pelvic Floor Disorders
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- University of OklahomaUniversity, hospital or other
- Collaborators
- Renovia, Inc.
- Study start
- 25 Mar 2021 (actual)
- Primary completion
- 26 Sep 2022 (actual)
- Study completion
- 26 Sep 2022 (actual)
- First posted
- 1 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The leva and PFDx devices accurately reflect pelvic floor motion consistent with TPUS evaluation. During a voluntary PFM contraction, the change in angle from a position of rest to maximal effort that is detected by each device is positively correlated with TPUS measurements and Modified Oxford scores.
Detailed description
Thirty women 18 years or older will be recruited from OB/GYN, FPMRS or other clinics. Following informed consent and successful screening, subjects will undergo testing as outlined below. Five subjects (all will be invited until five subjects have agreed) will return to clinic in 1-2 weeks to undergo repeat testing using all modalities.
After obtaining informed consent, subject information will be collected, including demographic data, BMI, and medical history (including ob/gyn history). Subjects will complete urinalysis for pregnancy. Subjects will also complete the Pelvic Floor Distress Inventory (PFDI-20) questionnaire. All subjects will undergo a complete pelvic examination including pelvic organ prolapse quantification (POP-Q), a digital assessment of PFM strength (Modified Oxford Scale) and receive a TPUS. Subjects will also complete a series of PFM contractions using the leva and PFDx devices to measure angle changes, and undergo vaginal assessment with a perineomter.
Pelvic floor muscle assessment Prior to recording device measurements, a correct pelvic floor muscle contraction will be verified via manual pelvic floor assessment. Subjects will be instructed to perform a "lift-and-squeeze" maneuver of the pelvic floor, and correct PFM contraction will be verified by the primary examiner (LHQ). PFM strength will then be assessed via digital palpation by the examiner inserting the first and/or second fingers approximately 4 cm into the vagina and palpating the right and left PFM during contraction. Strength will be graded according to the 6-point Modified Oxford Scale (0=no contraction; 1='flicker'; 2=weak; 3=moderate; 4=good; 5=strong). The mean score of the right and left sides of the vagina will be calculated and used for correlation analysis.
Perineometry PFM strength will be measured using a Peritron™ perineometer, which is a 28mm diameter compressible probe connected to a handheld microprocessor. It provides readings of pelvic floor contraction in cm of H20 with precision up to one decimal point, and it has been demonstrated to show reproducible and reliable measurements. The resting vaginal pressure and two peak pressures will be measured. For this study, PFM strength is defined as the augmented vaginal pressure, calculated by measuring the average of 2 peak pressures minus the resting vaginal pressure.
TPUS measurements TPUS imaging will be completed at the time of the study visit using the BK Medical Ultrafocus (Peabody, MA) and 8802 transperineal transducer. The probe will be covered with ultrasound gel and a probe cover. All ultrasound studies will be performed in the office setting with the patient in the dorsal lithotomy position, with hips flexed and abducted. No preparation is required, and no rectal or vaginal contrast will be used. Patients will be instructed to arrive at the office with a partially full bladder and to avoid excessive pressure on surrounding structures that might distort the anatomy. In the sagittal view, dynamic ultrasound parameters will be measured relative to a horizontal reference line at the level of the infero-posterior margin of the pubic symphysis. Dynamic images will be obtained during PFM contractions and at rest. At least 3 cycles of PFM contraction and relaxation will be recorded for each individual.
Baseline assessment will be performed at rest, then with 3 maximum-effort voluntary contraction (MVC). Ultrasound measurements will include: Anterior-posterior distance (APD) of the levator hiatus to the pubic bone (primary aim), levator urethra gap (LUG), distance from bladder neck to the pubic bone and distance of the midurethra to the pubic bone. Urethral angle at rest and with max contraction will also be measured. The cravioventral shift of the levator plate relative to a vertical line of reference relative to the anorectal angle will also be measured.
Leva measurements Subjects will be instructed on proper insertion and placement of the leva device. The examiner will assist with device placement, as needed. With the leva inserted, subjects will assume a standing position. Subjects will complete a series of pelvic floor muscle training (five lifts for 15 seconds of maximum lift, followe by 15 seconds of rest).
PFDx measurements The examiner will place the PFDx in the vagina, ensuring the ring component is positioned at the fornix with the extension running the length of vagina and out of the body. With the device retained in the vagina, subjects will assume a standing position. Angle measurements will be recorded at rest and with maximal voluntary 'lift-and-squeeze' contraction. These measurements will be repeated at least 3 times with 1-minute rest between each measurement.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Device usage | Experimental | Device: PFDx device and leva deviceAll participants will complete a survey and undergo an evaluation to test the movement of their pelvic floor with the PFDx device and leva device |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Female
- 18 years of age or older
- Presence of a vagina
- Ability to read and write English
- BMI <30
Key exclusion criteria (4 listed)
- Inability to perform a kegel exercise
- Pelvic organ prolapse greater than ICS POP-Q Stage II
- Known, untreated pelvic, vaginal or urinary tract infection
- Currently pregnant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PFDx device and leva deviceParticipants will use the leva device, PFDx device and undergo ultrasound measurements during pelvic floor motion to compare the three measurements. | Device | Device usage |
Primary outcome
Validate leva measurements with transperineal ultrasound (TPUS)
Time frame: Through final study visit (about 3 months)
During a voluntary pelvic floor muscle contraction, the change in angle from a position of rest to maximal effort that is detected by the leva device will be compared to the change in distance from the pubic bone to the levator plate measured by 2D TPUS during the same task.
9 secondary outcomes
Compare leva angle change measurements with Modified Oxford, Brinks
Time frame: Through final study visit (about 3 months)
Compare PFDx angle change measurements with Modified Oxford, Brinks
Time frame: Through final study visit (about 3 months)
Compare PFDx to a perineometer
Time frame: Through final study visit (about 3 months)
Compare leva to a perineometer
Time frame: Through final study visit (about 3 months)
Determine the test-retest reliability of Manual muscle testing angle measurements over 2 time points
Time frame: Through final study visit (about 3 months)
Determine the test-retest reliability of perineometry angle measurements over 2 time points
Time frame: Through final study visit (about 3 months)
Determine the test-retest reliability of ultrasound angle measurements over 2 time points
Time frame: Through final study visit (about 3 months)
Determine the test-retest reliability of leva angle measurements over 2 time points
Time frame: Through final study visit (about 3 months)
Determine the test-retest reliability of PFDx angle measurements over 2 time points
Time frame: Through final study visit (about 3 months)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jun 2023.
- Individual participant dataSharing planned: No. No plans to share information
Related trials for Pelvic Floor Disorders
Not yet recruiting
Transcutaneous Tibial Nerve Stimulation for Urinary Incontinence After Radical Prostatectomy
Urinary Incontinence (UI), Prostatectomy
Recruiting
Comparing the Effect of Two Types of Pelvic Floor Muscle Stimulation Devices to Improve Symptoms of Urinary Incontinence in Women.
Urinary Incontinence, Mixed Urinary Incontinence
RecruitingPhase 2
Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy
Erectile Dysfunction Following Radical Prostatectomy, Prostate Cancer
Recruiting
The Effects of Expiratory Muscle Strength Training in Women With Stress Urinary Incontinence
Stress Urinary Incontinence (SUI)
Recruiting
Effects Of Core Canister Training in Pregnant Women With History of Gestational Diabetes Mellitus
Antenatal Care Model, Gestatiaonl Diabetes Mellitus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lieschen Quiroz, MD principal investigator
University of Oklahoma HSC
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PFDx device and leva device in people with Pelvic Floor Disorders, run by University of Oklahoma at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Validate leva measurements with transperineal ultrasound (TPUS) (time frame: Through final study visit (about 3 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jun 2023.